CURX

Company Overview — What Does Curanex Pharmaceuticals Inc Do?

Curanex is a developmental stage pharmaceutical company dedicated to discovering, developing and commercializing innovative botanical drugs to treat patients suffering from inflammatory diseases. Our mission is to address significant unmet medical needs and improve patients’ lives by harnessing the power of natural substances. We are dedicated to discovering, developing and commercializing botanical medicines for treating patients with immune and inflammatory diseases and to develop therapies that may offer potential benefits to patients with unmet clinical needs in various fields, such as autoimmune diseases, metabolic diseases and viral infections. Our founders and related research personnel have been devoted to natural substances (“phytomedicine”) since 1996. Based on their knowledge and experience of natural substances and relevant technologies, they developed a proprietary platform for identifying, extracting and optimizing novel anti-inflammatory compounds from medicinal plants. We believe that this platform will allow us to create a pipeline of botanical drug candidates with potentially unique mechanisms of action to address unmet medical needs. Our lead drug candidate, Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant with a long history of human use. Phyto-N has a long history of use in Chinese traditional medicine, which focuses on an alternative herbal medical practice, and has shown positive results in animal models of multiple inflammatory diseases. Our objective is to prioritize the development of Phyto-N and its active compounds, to conduct further preclinical and clinical studies to evaluate its therapeutic potential and safety profile, and if warranted, to seek the necessary regulatory approval in order to commercialize Phyto-N. Specifically, we aim to establish proof-of-concept for our botanical drug development platform to bring therapies that will improve life of patients who currently have limited or no effective treatment options and to generate value for our stockholders. Our current drug development pipeline encompasses seven core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (“NAFLD”), and gout. If successfully developed and approved, Phyto-N may improve the lives of many patients worldwide. However, our research to date has been limited to preclinical studies for each of these indications. Our initial business plan is to submit an Investigational New Drug application (“IND”) for the treatment of ulcerative colitis in the first half of 2026. If allowed to proceed by the U.S. Food and Drug Administration (“FDA”), a Phase I trial will be initiated 30 days post-IND submission. If the Phase I trial is completed with positive results, we intend to proceed with a Phase II trial for ulcerative colitis as our lead indication. Contingent upon the success of our ulcerative colitis trials, available funding, and other strategic considerations, Curanex may subsequently initiate additional Phase II trials in other high-value indications such as atopic dermatitis, coronavirus (COVID-19), gout, diabetes, and NAFLD. This multiple indication strategy represents our long-term vision to explore and maximize the value of Phyto-N and build a robust pipeline of botanical drug candidates targeting inflammatory diseases. The successful completion of these clinical trials could position Phyto-N as a potential botanical drug candidate for multiple inflammatory indications, addressing specific unmet medical needs. If approved, Phyto-N could provide patients with new treatment options for various inflammatory conditions. As we progress towards clinical development, we will continue to invest in translational research to further elucidate the mechanisms of action, biomarkers, and patient stratification strategies for Phyto-N. These efforts will support our precision medicine approach and help us optimize the design and execution of our clinical trials to improve the chances of success. However, the process for conducting clinical trials is uncertain and there is no assurance that our clinical development activities will meet our planned timelines. There is also no assurance that we will be successful in obtaining FDA regulatory approval, in obtaining sufficient funds to pursue our growth strategy, and in commercialization of our lead or other product candidates. As a company that is developing botanical drugs, we may face challenges that similar companies experienced in the past with obtaining regulatory approval, as the development and approval process for botanical drugs involves additional challenges, including, but not limited to the complex nature of botanical extracts, which may contain multiple active compounds, making it difficult to identify and characterize all active ingredients, challenges in standardization and quality control due to natural variations in plant materials, difficulties in predicting pharmacokinetics and potential drug interactions due to the complex composition of botanical extracts, and manufacturing complexities in scaling up production while maintaining consistency and quality. Currently only two (2) botanical drugs have received FDA approval, such as Veregen® (sinecatechins), a green tea extract for the treatment of genital and perianal warts, and Fulyzaq®/Mytesi® (crofelemer), derived from the Croton lechleri tree, for managing diarrhea in HIV/AIDS patients on antiretroviral therapy. This limited number of approvals highlights both the innovative nature of our approach and the potential challenges in obtaining regulatory approval. These challenges involve additional costs and may result in delays, or failure to obtain the required FDA regulatory approval. --- Curanex was originally incorporated under the laws of the State of New York on June 1, 2018 under thename “Durand Damiel Health Inc,” focusing on research and development (R&D) of health products and botanical medicines. On October 24, 2023, the Company changed its name to “Fordman Pharma Inc.,” and on November 9, 2023, the Company changed its name to Curanex Pharmaceuticals Inc and changed its focus on discovering, developing and commercializing innovative botanical drugs for major unmet needs to treat patients suffering from inflammatory diseases. Our principal executive offices are located in Jericho, NY. Curanex Pharmaceuticals Inc (CURX) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jun Liu, headquartered in JERICHO, New York. With a market capitalization of $14M, CURX is one of the notable companies in the Healthcare sector.

Curanex Pharmaceuticals Inc (CURX) Stock Rating — Reduce (April 2026)

As of April 2026, Curanex Pharmaceuticals Inc receives a Reduce rating with a composite score of 27.6/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CURX ranks #3,438 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Curanex Pharmaceuticals Inc ranks among stocks, placing it in the top 10% of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CURX Stock Price and 52-Week Range

Curanex Pharmaceuticals Inc (CURX) currently trades at $0.46. The stock lost $0.01 (1.3%) in the most recent trading session. The 52-week high for CURX is $9.18, which means the stock is currently trading -94.9% from its annual peak. The 52-week low is $0.26, putting the stock 77.1% above its annual trough. Recent trading volume was 46K shares, suggesting relatively thin trading activity.

Is CURX Overvalued or Undervalued? — Valuation Analysis

Curanex Pharmaceuticals Inc (CURX) carries a value factor score of 17/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.09x, versus the sector average of 2.75x.

At current multiples, Curanex Pharmaceuticals Inc trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Curanex Pharmaceuticals Inc Profitability — ROE, Margins, and Quality Score

Curanex Pharmaceuticals Inc (CURX) earns a quality factor score of 28/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -150.6%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -145.9% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CURX Debt, Balance Sheet, and Financial Health

Curanex Pharmaceuticals Inc has a debt-to-equity ratio of 3.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 81.93x, indicating strong short-term liquidity.

CURX has a beta of 1.39, meaning it is more volatile than the broader market — a $10,000 investment in CURX would be expected to move 39.2% more than the S&P 500 on any given day. The stability factor score for Curanex Pharmaceuticals Inc is 16/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Curanex Pharmaceuticals Inc Revenue and Earnings History — Quarterly Trend

In TTM 2026, Curanex Pharmaceuticals Inc reported revenue of $0 and earnings per share (EPS) of $-0.17. Net income for the quarter was $-4M. Operating income came in at $-4M.

In FY 2025, Curanex Pharmaceuticals Inc reported revenue of $0 and earnings per share (EPS) of $-0.17. Net income for the quarter was $-4M. Operating income came in at $-4M.

In Q3 2025, Curanex Pharmaceuticals Inc reported revenue of $0 and earnings per share (EPS) of $-0.04. Net income for the quarter was $-954,059. Operating income came in at $-951,327.

In Q2 2025, Curanex Pharmaceuticals Inc reported revenue of $0 and earnings per share (EPS) of $0.00. Net income for the quarter was $-60,346. Operating income came in at $-57,658.

Over the past 4 quarters, Curanex Pharmaceuticals Inc has experienced revenue contraction from $0 to $0. Investors analyzing CURX stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CURX Dividend Yield and Income Analysis

Curanex Pharmaceuticals Inc (CURX) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CURX Momentum and Technical Analysis Profile

Curanex Pharmaceuticals Inc (CURX) has a momentum factor score of 31/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 50/100 reflects moderate short selling activity.

CURX vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Curanex Pharmaceuticals Inc (CURX) ranks #— out of 838 stocks based on the Blank Capital composite score. This places CURX in the top decile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CURX against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CURX vs S&P 500 (SPY) comparison to assess how Curanex Pharmaceuticals Inc stacks up against the broader market across all factor dimensions.

CURX Next Earnings Date

No upcoming earnings date has been announced for Curanex Pharmaceuticals Inc (CURX) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CURX? — Investment Thesis Summary

The quantitative profile for Curanex Pharmaceuticals Inc suggests caution. The quality score of 28/100 flags below-average profitability. The value score of 17/100 indicates premium valuation. Momentum is weak at 31/100, a headwind for near-term performance. High volatility (stability score 16/100) increases portfolio risk.

In summary, Curanex Pharmaceuticals Inc (CURX) earns a Reduce rating with a composite score of 27.6/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CURX stock.

Related Resources for CURX Investors

Explore more research and tools: CURX vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CURX head-to-head with peers: CURX vs AZN, CURX vs SLGL, CURX vs VMD.